Payment overview · 2025
General Payments
$1,020.83
40 reported records · 8 companies
Healthcare provider profile · identity verified
Mark Azbel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1306847405
Verified facts
What the public records show
CMS Open Payments records show Mark Azbel, M.D. received $1,020.83 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Linzess, Rexulti, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 880 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 526 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viibryd by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $398.31 | 39.0% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $228.78 | 22.4% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $217.98 | 21.4% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.79 | 7.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.88 | 2.1% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $17.78 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.77 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $982.29 | 39 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $228.78 | 14 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $217.98 | 12 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $202.13 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $202.13 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $119.33 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 285 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 69 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 880 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
285 | 58 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
880 | 129 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
526 | 65 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
125 | 33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1636 | 226 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1442 | 191 |
| Metoprolol Succinate | Metoprolol Succinate | 1329 | 175 |
| Furosemide | Furosemide | 1134 | 171 |
| Losartan Potassium | Losartan Potassium | 1031 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 968 | 118 |
| Linzess | Linaclotide | 880 | 129 |
| Eliquis | Apixaban | 839 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 756 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 753 | 112 |
| Metoprolol Tartrate | Metoprolol Tartrate | 724 | 95 |
| Hydralazine Hcl | Hydralazine Hcl | 707 | 130 |
| Gabapentin | Gabapentin | 706 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 702 | 90 |
| Clopidogrel | Clopidogrel Bisulfate | 682 | 81 |
| Metformin Hcl | Metformin Hcl | 661 | 83 |
| Diclofenac Sodium | Diclofenac Sodium | 658 | 152 |
| Escitalopram Oxalate | Escitalopram Oxalate | 656 | 91 |
| Vascepa | Icosapent Ethyl | 634 | 81 |
| Omeprazole | Omeprazole | 539 | 72 |
| Carvedilol | Carvedilol | 536 | 66 |
| Synthroid | Levothyroxine Sodium | 526 | 65 |
| Zenpep | Lipase/Protease/Amylase | 501 | 78 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 474 | 71 |
| Donepezil Hcl | Donepezil Hcl | 435 | 62 |
| Dexlansoprazole Dr | Dexlansoprazole | 420 | 70 |
| Tradjenta | Linagliptin | 417 | 51 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 416 | 148 |
| Quetiapine Fumarate | Quetiapine Fumarate | 403 | 62 |
| Ranolazine Er | Ranolazine | 398 | 49 |
| Trazodone Hcl | Trazodone Hcl | 368 | 58 |
| Entresto | Sacubitril/Valsartan | 363 | 46 |
| Potassium Chloride | Potassium Chloride | 359 | 44 |
| Myrbetriq | Mirabegron | 336 | 37 |
| Memantine Hcl Er | Memantine Hcl | 311 | 40 |
| Sertraline Hcl | Sertraline Hcl | 309 | 36 |
| Glimepiride | Glimepiride | 293 | 34 |
| Mirtazapine | Mirtazapine | 289 | 56 |
| Creon | Lipase/Protease/Amylase | 285 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 282 | 54 |
| Silver Sulfadiazine | Silver Sulfadiazine | 280 | 120 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 279 | 38 |
| Simvastatin | Simvastatin | 271 | 36 |
| Azithromycin | Azithromycin | 262 | 200 |
| Memantine Hcl | Memantine Hcl | 256 | 34 |
| Allopurinol | Allopurinol | 248 | 43 |
| Icosapent Ethyl | Icosapent Ethyl | 238 | 44 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 234 | 55 |
| Famotidine | Famotidine | 232 | 43 |
| Nebivolol Hcl | Nebivolol Hcl | 223 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 220 | 122 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 212 | 25 |
| Prednisone | Prednisone | 207 | 44 |
| Glipizide Er | Glipizide | 200 | 26 |
| Valsartan | Valsartan | 199 | 27 |
| Lisinopril | Lisinopril | 188 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 32 |
| Ammonium Lactate | Ammonium Lactate | 176 | 81 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 174 | 20 |
| Tramadol Hcl | Tramadol Hcl | 170 | 58 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 169 | 28 |
| Repaglinide | Repaglinide | 164 | 19 |
| Clonidine Hcl | Clonidine Hcl | 162 | 42 |
| Lactulose | Lactulose | 158 | 40 |
| Nifedipine Er | Nifedipine | 150 | 19 |
| Spironolactone | Spironolactone | 150 | 25 |
| Ezetimibe | Ezetimibe | 147 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 147 | 80 |
| Labetalol Hcl | Labetalol Hcl | 145 | 17 |
| Januvia | Sitagliptin Phosphate | 144 | 22 |
| Ozempic | Semaglutide | 142 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 139 | 105 |
| Finasteride | Finasteride | 137 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 134 | 17 |
| Levetiracetam | Levetiracetam | 132 | 17 |
| Lorazepam | Lorazepam | 132 | 32 |
| Enalapril Maleate | Enalapril Maleate | 130 | 19 |
| Xarelto | Rivaroxaban | 128 | 15 |
| Trulance | Plecanatide | 125 | 33 |
| Olanzapine | Olanzapine | 122 | 15 |
| Torsemide | Torsemide | 118 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 20 |
| Meclizine Hcl | Meclizine Hcl | 116 | 37 |
| Risperidone | Risperidone | 114 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 112 | 16 |
| Cefdinir | Cefdinir | 110 | 80 |
| Hydrocortisone | Hydrocortisone | 110 | 70 |
| Primidone | Primidone | 110 | 17 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 105 | 27 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 104 | 14 |
| Meloxicam | Meloxicam | 104 | 52 |
| Nystatin | Nystatin | 103 | 44 |
| Telmisartan | Telmisartan | 100 | 12 |
| Atenolol | Atenolol | 97 | 12 |
| Procto-Med Hc | Hydrocortisone | 97 | 26 |
| Methenamine Hippurate | Methenamine Hippurate | 95 | 29 |
| Montelukast Sodium | Montelukast Sodium | 95 | 26 |
| Levofloxacin | Levofloxacin | 92 | 72 |
| Jentadueto | Linagliptin/Metformin Hcl | 91 | suppressed |
| Lidocaine | Lidocaine | 91 | 25 |
| Alcohol Pads | Alcohol Antiseptic Pads | 88 | 26 |
| Jardiance | Empagliflozin | 88 | 14 |
| Dutasteride | Dutasteride | 87 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 11 |
| Alendronate Sodium | Alendronate Sodium | 84 | 13 |
| Dexilant | Dexlansoprazole | 84 | 14 |
| Clonazepam | Clonazepam | 83 | 26 |
| Mupirocin | Mupirocin | 83 | 60 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 83 | 11 |
| Metformin Hcl Er | Metformin Hcl | 82 | suppressed |
| Ssd | Silver Sulfadiazine | 81 | 57 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 79 | 14 |
| Glipizide | Glipizide | 78 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 77 | 42 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | 13 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 74 | 15 |
| Ramipril | Ramipril | 72 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 72 | suppressed |
| Proctozone-Hc | Hydrocortisone | 71 | 20 |
| Cyclosporine | Cyclosporine | 70 | 11 |
| Digoxin | Digoxin | 69 | 11 |
| Gemtesa | Vibegron | 69 | 16 |
| Methimazole | Methimazole | 68 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 66 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 65 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | suppressed |
| Ketoconazole | Ketoconazole | 64 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 24 |
| Cilostazol | Cilostazol | 63 | suppressed |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Nitroglycerin | Nitroglycerin | 63 | 20 |
| Nitroglycerin Patch | Nitroglycerin | 63 | 19 |
| Rivastigmine | Rivastigmine | 61 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 11 |
| Clonidine | Clonidine | 58 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 57 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | suppressed |
| Clotrimazole | Clotrimazole | 57 | 28 |
| Loperamide | Loperamide Hcl | 57 | 31 |
| Metolazone | Metolazone | 57 | suppressed |
| Alprazolam | Alprazolam | 56 | 12 |
| Colchicine | Colchicine | 54 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 42 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 50 | 20 |
| Nexium | Esomeprazole Magnesium | 50 | suppressed |
| Brilinta | Ticagrelor | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 49 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 39 |
| Celecoxib | Celecoxib | 43 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | 19 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Sucralfate | Sucralfate | 43 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 27 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Invokana | Canagliflozin | 38 | suppressed |
| Irbesartan | Irbesartan | 37 | suppressed |
| Livalo | Pitavastatin Calcium | 37 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 36 | suppressed |
| Bystolic | Nebivolol Hcl | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | 11 |
| Bumetanide | Bumetanide | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 30 |
| Tirosint | Levothyroxine Sodium | 35 | suppressed |
| Eplerenone | Eplerenone | 34 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Mupirocin | Mupirocin Calcium | 33 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Nyamyc | Nystatin | 31 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 24 |
| Megestrol Acetate | Megestrol Acetate | 28 | 18 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Rytary | Carbidopa/Levodopa | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 26 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 25 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 25 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Xifaxan | Rifaximin | 25 | 12 |
| Baclofen | Baclofen | 24 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 24 | suppressed |
| Felodipine Er | Felodipine | 24 | suppressed |
| Risperidone Odt | Risperidone | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Gralise | Gabapentin | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Acetazolamide | Acetazolamide | 21 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 11 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Benicar | Olmesartan Medoxomil | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Unithroid | Levothyroxine Sodium | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Acarbose | Acarbose | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Edarbi | Azilsartan Medoxomil | 16 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | 11 |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Procrit | Epoetin Alfa | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Pacerone | Amiodarone Hcl | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Viibryd | Vilazodone Hcl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Diovan | Valsartan | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 11 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Norvasc | Amlodipine Besylate | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Silodosin | Silodosin | 11 | suppressed |
| Toviaz | Fesoterodine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,020.83 · 40 records | ABBVIE INC. | CREON, FARXIGA, GEMTESA, LINZESS, OTEZLA, REPATHA, REXULTI, Topical Oxygen Chamber for extremities, XIFAXAN | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error